middle.news
How Paradigm’s Phase 2 Study Validates iPPS Impact on Osteoarthritis Biomarkers
12:32pm on Wednesday 28th of January, 2026 AEDT
•
Healthcare
Read Story
How Paradigm’s Phase 2 Study Validates iPPS Impact on Osteoarthritis Biomarkers
12:32pm on Wednesday 28th of January, 2026 AEDT
Key Points
Phase 2 iPPS biomarker study published in Arthritis Research & Therapy
Significant reductions in cartilage degradation and inflammation biomarkers
Durable biological effects observed months after treatment
Supports ongoing Phase 3 PARA_OA_012 clinical trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PARADIGM BIOPHARMACEUTICALS LIMITED.. (ASX:PAR)
OPEN ARTICLE